The Discovery of Prostate Specific Antigen as a Biomarker for the Early Detection of Adenocarcinoma of the Prostate

Journal of Urology

Volumn 176, Issue 6, 2006, Pages 2383-2385

  Makarov, Danil V ^a   Carter, H Ballentine ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

biological markers; history; prostate specific antigen; prostatic neoplasms

Indexed keywords

BIOLOGICAL MARKER; PROSTATE SPECIFIC ANTIGEN;

ADENOCARCINOMA; ARTICLE; CANCER DIAGNOSIS; FOLLOW UP; HUMAN; MEDICAL LITERATURE; MEDICAL PRACTICE; PRIORITY JOURNAL; PROSTATE CARCINOMA;

ADENOCARCINOMA; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 33750532921     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2006.08.019     Document Type: Article

References (8)

1. Wang M.C., Papsidero L.D., and Chu T.M. Prostate-specific antigen, p30, gamma-seminoprotein, and E1. Prostate 24 (1994) 107
2. Stamey T.A., Yang N., Hay A.R., McNeal J.E., Freiha F.S., and Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 317 (1987) 909
3. Stamey T.A., Caldwell M., McNeal J.E., Nolley R., Hemenez M., and Downs J. The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years?. J Urol 172 (2004) 1297
4. Myrtle J.F. Normal levels of prostate-specific antigen (PSA). In: Catalona W.J., Coffey D.S., and Karr J.P. (Eds). Prostate Cancer Working Group: Clinical Aspects of Prostate Cancer: Assessment of New Diagnostic and Management Procedures (1989), Elsevier, New York 183-189 Proceedings of a Workshop of the Prostate Cancer Working Group of the National Cancer Institute's Organ Systems Program, held October 16-19, 1988, at Prout's Neck, Maine, U.S.A. and Organ Systems Program (National Cancer Institute)
5. Cooner W.H., Mosley B.R., Rutherford Jr. C.L., Beard J.H., Pond H.S., Terry W.J., et al. Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen. J Urol 143 (1990) 1146
6. Catalona W.J., Smith D.S., Ratliff T.L., Dodds K.M., Coplen D.E., Yuan J.J., et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 324 (1991) 1156
7. Gann P.H., Hennekens C.H., and Stampfer M.J. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA 273 (1995) 289
8. Thompson I.M., Pauler D.K., Goodman P.J., Tangen C.M., Lucia M.S., Parnes H.L., et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med 350 (2004) 2239